Page 1 of 1

My favorite abstract

Posted: Thu Nov 05, 2020 4:47 pm
by biopearl123
Every year I ask Dr. Scarlett if there is evidence with the observed disease modification, if some statement can be made regarding the progression of MDS and the transformation to AML can be made. Every year he says there is not enough data. Fair enough. But this year we see an exciting new abstract from Dr. Wen Ma. Dr. Ma's studies can only be described as elegant. Here is this years submission to ASH:

https://ash.confex.com/ash/2020/webprog ... 40771.html

Note also the last author, Dr. Catriona Jamieson and the ties to Forty Seven and CRIM.

Regards to all, bp

Re: My favorite abstract

Posted: Thu Nov 05, 2020 7:46 pm
by biopearl123
Another potential combo?

About dasatinib from Wikipedia:

“ Dasatinib was developed by collaboration of Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd,[13][14][15] and named for Bristol-Myers Squibb research fellow Jagabandhu Das, whose program leader says that the drug would not have come into existence had he not challenged some of the medicinal chemists' underlying assumptions at a time when progress in the development of the molecule had stalled.[16]”

Re: My favorite abstract

Posted: Thu Nov 05, 2020 11:08 pm
by muskateer
They are saying disease modification a lot at the ER! Right? Thanks.

Re: My favorite abstract

Posted: Thu Nov 05, 2020 11:24 pm
by biopearl123
Right. A lot. A whole lot. The potential to change the entire natural history of these diseases is apparent. Including impacting the evolution to AML.

Re: My favorite abstract

Posted: Fri Nov 06, 2020 3:55 pm
by muskateer
Thanks Pearl :-)